Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million

This article was originally published in The Pink Sheet Daily

Executive Summary

Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.

You may also be interested in...



AstraZeneca Hits Anti-Infective Target With Arrow Acquisition

Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.

AstraZeneca Hits Anti-Infective Target With Arrow Acquisition

Acquisition of U.K. biotech reflects AstraZeneca's core therapeutic focus in infection, the company says.

Acomplia User Fee Date For Weight Loss Is April 26

Sanofi-Aventis has not determined a timetable for responding to FDA’s “not approvable” letter for a smoking cessation claim.

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel